NCT05281471Phase 3Recruiting

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-12Estimated

Enrollment · participants186Estimated

Source updated2026-08-26Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-07-10 · 1 field changed

Primary completion date changed

− Before

~~Jun 2026~~

+ After

Dec 2026

Check registry source

Study details

Conditions studied

Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; High-grade Serous Ovarian Cancer; Endometrioid Ovarian Cancer; Ovarian Clear Cell Carcinoma

Treatments or interventions studied

olvimulogene nanivacirepvecBiologicalAlso known as GL-ONC1 and GLV-1h68
Platinum chemotherapy: carboplatin (preferred) or cisplatinDrug
Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicinDrug
Bevacizumab (or biosimilar)Drug

Primary outcomes · main study measures

Read the study measures

measure: Progression-free survival (PFS) by RECIST 1.1 in the Intention-to-Treat (ITT) population (all randomized participants regardless of whether they received any dose of treatment); description: To assess progression-free survival from time of randomization until first documented disease progression based on radiological assessment or death from any cause.; timeFrame: From date of randomization up to 12 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history